More importantly, subgroup analysis showed that SGLT-2 inhibitors are more effective in reducing VAT, SAT and ecpotic liver fat in patients with T2DM combined with NAFLD, but due to significant heterogeneity, we should treat this result with caution. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.